Trimel tumbles on FDA CompleoTRT delay
This article was originally published in Scrip
Executive Summary
Shares of Trimel Pharmaceuticals tumbled about 34.5% on 17 January on the Toronto Stock Exchange after the company revealed the FDA has delayed by three months its decision on the company's new drug application (NDA) for CompleoTRT, a bioadhesive intranasal gel testosterone product intended to treat hypogonadal patients.